Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer

Vaccine

Volumn 32, Issue 15, 2014, Pages 1654-1660

  Fransen, Marieke F ^a   Cordfunke, Robert A ^a   Sluijter, Marjolein ^a   Van Steenbergen, Mies J ^b   Drijfhout, Jan W ^a   Ossendorp, Ferry ^a   Hennink, Wim E ^b   Melief, Cornelis J M ^a,c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c ISA Pharmaceuticals   (Netherlands)

Author keywords

Cancer immunotherapy; Microparticles; Monoclonal antibodies; Side effects; Slow release

Indexed keywords

CD40 AGONISTIC ANTIBODY; CD8 ANTIGEN; DEXTRAN; LYMPHOCYTE ANTIBODY; MONTANIDE ISA 51; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL ACTIVITY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; DRUG DELIVERY SYSTEM; INFLAMMATION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SLOW RELEASE FORMULATION; T LYMPHOCYTE ACTIVATION;

CANCER IMMUNOTHERAPY; MICROPARTICLES; MONOCLONAL ANTIBODIES; SIDE-EFFECTS; SLOW-RELEASE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; CD8-POSITIVE T-LYMPHOCYTES; DELAYED-ACTION PREPARATIONS; DEXTRANS; HYBRIDOMAS; IMMUNOTHERAPY; MALE; MANNITOL; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; OLEIC ACIDS;

EID: 84895886897     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.01.056     Document Type: Article

References (38)

1. Boon T., De Plaen E., Lurquin C., Van den Eynde B., van der Bruggen P., Traversari C., Amar-Costesec A., Van Pel A. Identification of tumour rejection antigens recognized by T lymphocytes. Cancer Surv 1992, 13:23-37.
2. Van Pel A., Boon T. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. PNAS 1982, 79(15):4718-4722.
3. Vigneron N., Stroobant V., Van den Eynde B.J., van der Bruggen P. Database of T cell-defined human tumor antigens: the 2013 update. Cancer Immun 2013, 13:15.
4. Hargadon K.M., Brinkman C.C., Sheasley-O'neill S.L., Nichols L.A., Bullock T.N., Engelhard V.H. Incomplete differentiation of antigen-specific CD8 T cells in tumor-draining lymph nodes. J Immunol 2006, 177(9):6081-6090.
5. Fuchs E.J., Matzinger P. Is cancer dangerous to the immune system?. Semin Immunol 1996, 8(5):271-280.
6. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., Akerley W., van den Eertwegh A.J., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(8):711-723.
7. Melief C.J., Toes R.E., Medema J.P., van der Burg S.H., Ossendorp F., Offringa R. Strategies for immunotherapy of cancer. Adv Immunol 2000, 75:235-282.
8. Melief C.J. Cancer immunotherapy by dendritic cells. Immunity 2008, 29(3):372-383.
9. Suntharalingam G., Perry M.R., Ward S., Brett S.J., Castello-Cortes A., Brunner M.D., Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006, 355(10):1018-1028.
10. Fransen M.F., Sluijter M., Morreau H., Arens R., Melief C.J. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res 2011, 17(8):2270-2280.
11. Freiberg S., Zhu X.X. Polymer microspheres for controlled drug release. Int J Pharm 2004, 282(1-2):1-18.
12. Hoffman A.S. The origins and evolution of "controlled" drug delivery systems. J Controlled Release 2008, 132(3):153-163.
13. Ye M., Kim S., Park K. Issues in long-term protein delivery using biodegradable microparticles. J Controlled Release 2010, 146(2):241-260.
14. Bysell H., Mansson R., Hansson P., Malmsten M. Microgels and microcapsules in peptide and protein drug delivery. Adv Drug Delivery Rev 2011, 63(13):1172-1185.
15. Siepmann J., Siepmann F. Modeling of diffusion controlled drug delivery. J Controlled Release 2012, 161(2):351-362.
16. Ford Versypt A.N., Pack D.W., Braatz R.D. Mathematical modeling of drug delivery from autocatalytically degradable PLGA microspheres-a review. J Controlled Release 2013, 165(1):29-37.
17. Fredenberg S., Wahlgren M., Reslow M., Axelsson A. The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems-a review. Int J Pharm 2011, 415(1-2):34-52.
18. Varshosaz J. Dextran conjugates in drug delivery. Expert Opin Drug Delivery 2012, 9(5):509-523.
19. Mehvar R. Dextrans for targeted and sustained delivery of therapeutic and imaging agents. J Controlled Release 2000, 69(1):1-25.
20. De Groot C.J., Cadee J.A., Koten J.W., Hennink W.E., Den Otter W. Therapeutic efficacy of IL-2-loaded hydrogels in a mouse tumor model. Int J Cancer 2002, 98(1):134-140.
21. Franssen O., Vandervennet L., Roders P., Hennink W.E. Degradable dextran hydrogels: controlled release of a model protein from cylinders and microspheres. J Controlled Release 1999, 60(2-3):211-221.
22. Vlugt-Wensink K.D., Jiang X., Schotman G., Kruijtzer G., Vredenberg A., Chung J.T., Zhang Z., Versluis C., Ramos D., Verrijk R., Jiskoot W., Crommelin D.J., et al. In vitro degradation behavior of microspheres based on cross-linked dextran. Biomacromolecules 2006, 7(11):2983-2990.
23. Franssen O., Stenekes R.J., Hennink W.E. Controlled release of a model protein from enzymatically degrading dextran microspheres. J Controlled Release 1999, 59(2):219-228.
24. Rolink A., Melchers F., Andersson J. The SCID but not the RAG-2 gene product is required for S mu-S epsilon heavy chain class switching. Immunity 1996, 5(4):319-330.
25. Stenekes R.J., Franssen O., van Bommel E.M., Crommelin D.J., Hennink W.E. The preparation of dextran microspheres in an all-aqueous system: effect of the formulation parameters on particle characteristics. Pharm Res 1998, 15(4):557-561.
26. van DijkWolthuis W.N.E., Tsang S.K.Y., KettenesvandenBosch J.J., Hennink W.E. A new class of polymerizable dextrans with hydrolyzable groups: hydroxyethyl methacrylated dextran with and without oligolactate spacer. Polymer 1997, 38(25):6235-6242.
27. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
28. Lorentz K., Flatter B. Clinical application of a new method for the determination of aminoacylase in human serum. Clin Chim Acta 1975, 63(3):271-274.
29. Toes R.E., Blom R.J., van der Voort E., Offringa R., Melief C.J., Kast W.M. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res 1996, 56(16):3782-3787.
30. Johansen P., Corradin G., Merkle H.P., Gander B. Release of tetanus toxoid from adjuvants and PLGA microspheres: how experimental set-up and surface adsorption fool the pattern. J Controlled Release 1998, 56(1-3):209-217.
31. Cadee J.A., Van Luyn M.J., Brouwer L.A., Plantinga J.A., van Wachem P.B., de Groot C.J., Den Otter W., Hennink W.E. In vivo biocompatibility of dextran-based hydrogels. J Biomed Mater Res 2000, 50(3):397-404.
32. Sun G., Zhang X., Shen Y.I., Sebastian R., Dickinson L.E., Fox-Talbot K., Reinblatt M., Steenbergen C., Harmon J.W., Gerecht S. Dextran hydrogel scaffolds enhance angiogenic responses and promote complete skin regeneration during burn wound healing. PNAS 2011, 108(52):20976-20981.
33. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454(7203):436-444.
34. Piccard H., Muschel R.J., Opdenakker G. On the dual roles and polarized phenotypes of neutrophils in tumor development and progression. Crit Rev Oncol Hematol 2012, 82(3):296-309.
35. Rosenfeld E.L., Lukomskaya I.S. The splitting of dextran and isomaltose by animal tissues. Clin Chim Acta 1957, 2(2):105-114.
36. Warburg O., Wind F., Negelein E. The metabolism of tumors in the body. J Gen Physiol 1927, 8(6):519-530.
37. Flier J.S., Mueckler M.M., Usher P., Lodish H.F. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987, 235(4795):1492-1495.
38. De Groot C.J., Cadee J.A., Koten J.W., Hennink W.E., Den Otter W. Therapeutic efficacy of IL-2-loaded hydrogels in a mouse tumor model. Int J Cancer 2002, 98(1):134-140.